编辑丨王多鱼 排版丨水成文 论文首先阐述了 现代组学技术 是实现育种范式变革的基础。基因组学、代谢组学以及单细胞组学等研究方向的兴起，为我们提供了前所未有的能力去深入解析作 物的遗传信息和生命活动规律，从而揭示更多可用于性状精准改良的新位点 。与此同时， 高通量表型鉴定技术 （ HTP ） 利用无人机、传感器和自动化平台， 实现了对海量作物性状数据的快速、精准评估，从而高效地连接了基因型与表型，为筛选优良变异提供了关键支撑 。 在此基础上，论文详细论述了实现作物改良的强大工具。以 CRISPR 为代表的基因组编辑技术，已能够实现对作物基因组开展高效、精准的定向修饰，其跨尺 度、多维度的基因组设计能力将显著缩短育种周期，快速创造和聚合优良性状 。不仅如此， AI 驱动的蛋白质设计技术 正在兴起，它能够从头创造出自然界中不 存在的、具有特定功能的全新蛋白质 。这为开发新型抗病蛋白、实时监测作物健康的生物传感器或降解环境污染物的特制酶提供了可能，从而赋予作物突破性的 新功能 。 通过整合新技术促进潜在作物改良 作物改良中的基因组编辑技术 2025 年 7 月 24 日， 中国科学院遗传与发育生物学研究所 高彩霞 研 ...

Core Viewpoint - Chengdu's biopharmaceutical industry is experiencing rapid growth, positioning itself as a leading hub for innovation in the sector, prompting discussions on how to capitalize on this momentum and attract more high-caliber pharmaceutical companies [1][2]. Group 1: Industry Growth and Opportunities - The biopharmaceutical sector is witnessing an explosion of high-growth sub-sectors, with potential areas for development including nuclear medicine, where Chengdu has existing advantages and emerging representative companies [2][3]. - The integration of AI with biopharmaceuticals is seen as a potential avenue for disruptive innovation, with local resources in both AI and pharmaceuticals being leveraged to explore this intersection [2][3]. Group 2: Medical Device Sector Development - Chengdu is addressing its shortcomings in the medical device sector, with the establishment of a comprehensive service platform for medical devices and CDMO projects, which will enhance local testing capabilities [3]. - The medical device industry in China has significant growth potential, with a current "drug-device ratio" of 4:1 compared to 1:1 in Western countries, indicating room for expansion [3]. Group 3: Ecosystem and Structural Challenges - Chengdu's pharmaceutical ecosystem is nearly complete but lacks a top-tier production base among the national top 500 companies, which is essential for a full industrial chain [4]. - There are calls for a more robust ecosystem that supports continuous innovation in pharmaceuticals, emphasizing the need for systemic reforms to facilitate the establishment of international pharmaceutical companies [5][6]. Group 4: Policy and Regulatory Environment - The efficiency of regulatory processes is crucial for attracting pharmaceutical companies, as seen in the example of a large pharmaceutical firm choosing Suzhou due to streamlined customs processes [6]. - Improving policy details and regulatory frameworks could enable Chengdu to attract key enterprises more rapidly than other cities, enhancing its competitive edge in the biopharmaceutical landscape [6].